Related Experiment Video

Updated: Jun 13, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy

Jiping Zha1, Mark R Lackner

  • 1Department of Research Pathology, Genentech, Inc., South San Francisco, CA 94080, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 15, 2010
PubMed

Insights

Targeting the insulin-like growth factor receptor (IGF-1R) shows promise for cancer therapy. Early clinical trials indicate acceptable safety and some antitumor activity for IGF-1R inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin-like growth factor receptor (IGF-1R) signaling is crucial for neoplastic transformation driven by oncogenes.
  • Preclinical studies identify IGF-1R as a promising target for anticancer drug development.
  • Small molecules and antibodies targeting IGF-1R have advanced into clinical trials.

Purpose of the Study:

  • To review the role of IGF-1R signaling in cancer.
  • To highlight key findings from early clinical development of anti-IGF-1R agents.
  • To discuss strategies for optimizing anti-IGF-1R cancer therapy.

Main Methods:

  • Review of preclinical and clinical data on IGF-1R signaling in cancer.
  • Analysis of safety and efficacy profiles of IGF-1R targeting agents.
  • Evaluation of therapeutic strategies including patient and indication selection.

Main Results:

  • IGF-1R targeting agents demonstrate generally acceptable safety profiles as monotherapies.
  • Early clinical data suggest some evidence of antitumor activity.
  • Lessons learned from early development emphasize pathway-specific indications and biomarker-driven patient selection.

Conclusions:

  • IGF-1R is a validated therapeutic target in oncology.
  • Optimizing anti-IGF-1R therapy requires careful patient selection and combination strategies.
  • Further research should focus on predictive biomarkers and rational drug combinations.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...